Why Should I Vote On BetterDistricts?

Polling is a powerful tool to help our elected officials determine how they should vote.

Standard polling methods don't give you the control that you deserve. With BetterDistricts you can show your representative exactly how strongly a bill is supported in your community.

Send a clear signal on how you want your government to work.

 

H.R. 6717 - Depression Side Effect Labeling Awareness Act of 2018

Introduced: 2018-09-06
Bill Status: Referred to the House Committee on Energy and Commerce.
 
Summary Not Available

Full Text


115th CONGRESS
2d Session
H. R. 6717


    To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.


IN THE HOUSE OF REPRESENTATIVES

September 6, 2018

    Mr. Rush introduced the following bill; which was referred to the Committee on Energy and Commerce


A BILL

    To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Depression Side Effect Labeling Awareness Act of 2018”.

SEC. 2. Prominent drug labeling for increased risk of suicide or depression.

(a) In general.—Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following:

“(ee) If the warnings and precautions in the drug’s label include an increased risk of suicide or depression, unless such increased risk is presented prominently.”.

(b) Regulations.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall promulgate final regulations to carry out section 502(ee) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a). Before promulgating such regulations, the Secretary shall consult with stakeholders, including manufacturers of drugs.

(c) Delayed applicability.—Such section 502(ee) shall not apply until the Secretary of Health and Human Services has issued a final regulation under subsection (b).


Relevant News Stories And Blog Posts

Title Worth Reading

Vote on H.R. 6717

 

Activity in last 30 days